GELITA AG has established a center for biotechnology. At the Biotech Hub in Frankfurt am Main, biologists and biotechnologists work, among other things, on the development of proteins from biotechnological processes for applications in nutrition, cosmetics, and pharmaceutical and medical products. "Investing in CEUTA's Biotech Hub is a clear commitment to biotechnology, a key and future-oriented 21st-century technology that offers enormous innovation potential. It allows us to meet the growing demand of international markets sustainably and with new offers. At the same time, the new research laboratory underlines our commitment to innovation in our markets and our goal of sustainable, profitable growth", explained Dr. Sven Abend, CEO of GELITA AC, at the opening ceremony. GELITA collagen peptides from animal raw materials have recorded high growth rates in recent years. As a pioneer in the clinical research and production of specific bioactive collagen peptides, the company also plans to systematically expand its expertise in the field of biotechnology. A move that will secure its core business in the long term and open up new, lucrative market segments.
展开▼
